PROBE 2 assessed the safety and efficacy of switching to rilpivirine (RPV) plus darunavir/cobicistat (DRV/c) among people stably suppressed on three-drug ART without HBV co-infection.  48-week final analysis results are presented here, involving 80 participants in the early switch group and 80 participants in the late switch group.  Participants in the early switch group had been on cART for a median duration of 39 months (late switch group: 22 months); median duration of virologic suppression was 7 years.  Approximately a third of participants were already receiving a RPV-containing regimen while ~13% were taking DRV/c.  70 (87.5%) participants in the early group and 76 (94.8%) in the late group maintained viral load < 50 copies/mL.  Two individuals in the late group met criteria for confirmed virological withdrawal (CVW), however no treatment emergent resistance-associated mutations were identified.  Both had been on F/TAF plus DRV/c prior to switch, and both experienced viral blips (~80 copies/mL) during the study’s first phase.  Both resuppressed on a three-drug regimen.  Quantitative ultrasound (QUS) of the dominant heel scans indicated small bone stiffness increases in the early group (47.5% of participants in this group were taking tenofovir disoproxil fumarate prior to switch).  Modest serum lipid increases were observed but felt to be of little/no clinical relevance.  When analyzed by pre-switch ART backbone, lipid changes were significant only when the withdrawn backbone included tenofovir disoproxil fumarate.  No significant body weight changes were observed.